LadRx Corporation (LADX)

OTCMKTS: LADX · Delayed Price · USD
0.170
-0.005 (-2.86%)
Dec 5, 2022 4:00 PM EST - Market closed
-2.86%
Market Cap 7.66M
Revenue (ttm) n/a
Net Income (ttm) -12.95M
Shares Out 45.04M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 171,954
Open 0.185
Previous Close 0.175
Day's Range 0.156 - 0.185
52-Week Range 0.052 - 0.69
Beta 2.11
Analysts n/a
Price Target n/a
Earnings Date Nov 10, 2022

About LADX

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is head... [Read more]

Industry Biotechnology
Founded 1985
CEO Steven Kriegsman
Employees 3
Stock Exchange OTCMKTS
Ticker Symbol LADX
Full Company Profile

Financial Performance

Financial Statements

News

CytRx Corporation Relaunches as LadRx Corporation

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces ...

2 months ago - Business Wire

CytRx Comments on Quarterly Results and Recent Strategic Initiatives

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...

1 year ago - Business Wire

CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

1 year ago - Business Wire

CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Inv...

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

1 year ago - Business Wire

CytRx Comments on Quarterly Results and Year-to-Date Progress

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...

1 year ago - Business Wire

CytRx Comments on Fiscal Year 2020 Results and Highlights Strategic Progress

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

1 year ago - Business Wire

CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Dis...

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

2 years ago - Business Wire

CytRx Highlights Orphazyme's Acceleration of Pre-Launch Activities for Arimoclomol

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

2 years ago - Business Wire

CytRx Issues Statement Regarding Orphazyme’s Global Offering

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...

2 years ago - Business Wire

CytRx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomo...

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted...

2 years ago - Business Wire